Expression of the BAD pathway is a marker of triple-negative status and poor outcome

Triple-negative breast cancer (TNBC) has few therapeutic targets, making nonspecific chemotherapy the main treatment. Therapies enhancing cancer cell sensitivity to cytotoxic agents could significantly improve patient outcomes. A BCL2-associated agonist of cell death (BAD) pathway gene expression si...

Descripción completa

Detalles Bibliográficos
Autores principales: Boac, Bernadette M., Abbasi, Forough, Ismail-Khan, Roohi, Xiong, Yin, Siddique, Atif, Park, Hannah, Han, Mingda, Saeed-Vafa, Daryoush, Soliman, Hatem, Henry, Brendon, Pena, M. Juliana, McClung, E. Clair, Robertson, Sharon E., Todd, Sarah L., Lopez, Alex, Sun, Weihong, Apuri, Susmitha, Lancaster, Johnathan M., Berglund, Anders E., Magliocco, Anthony M., Marchion, Douglas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877530/
https://www.ncbi.nlm.nih.gov/pubmed/31767884
http://dx.doi.org/10.1038/s41598-019-53695-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877530/
https://www.ncbi.nlm.nih.gov/pubmed/31767884
http://dx.doi.org/10.1038/s41598-019-53695-0

Ejemplares similares